Managing hypertension in type 2 diabetes mellitus

被引:34
作者
Horr, Samuel [1 ]
Nissen, Steven [1 ]
机构
[1] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
关键词
diabetes mellitus; hypertension; pharmacology; BLOOD-PRESSURE; CARDIOVASCULAR OUTCOMES; DOUBLE-BLIND; ANTIHYPERTENSIVE TREATMENT; RESISTANT HYPERTENSION; RANDOMIZED-TRIAL; OLDER PATIENTS; RISK-FACTORS; AMLODIPINE; MORTALITY;
D O I
10.1016/j.beem.2016.06.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertension is a common problem in the diabetic population with estimates suggesting a prevalence exceeding 60%. Comorbid hypertension and diabetes mellitus are associated with high rates of macrovascular and microvascular complications. These two pathologies share overlapping risk factors, importantly central obesity. Treatment of hypertension is unequivocally beneficial and improves all-cause mortality, cardiovascular mortality, major cardiovascular events, and microvascular outcomes including nephropathy and retinopathy. Although controversial, current guidelines recommend a target blood pressure in the diabetic population of <140/90 mmHg, which is a similar target to that proposed for individuals without diabetes. Management of blood pressure in patients with diabetes includes both lifestyle modifications and pharmacological therapies. This article reviews the evidence for management of hypertension in patients with type 2 diabetes mellitus, and provides a recommended treatment strategy based on the available data. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:445 / 454
页数:10
相关论文
共 75 条
[1]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[2]   LONG-TERM EFFECTS OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR CAPTOPRIL ON METABOLIC CONTROL IN NONINSULIN-DEPENDENT DIABETES-MELLITUS [J].
ALKHAROUF, J ;
NALINIKUMARI, K ;
CORRY, D ;
TUCK, M .
AMERICAN JOURNAL OF HYPERTENSION, 1993, 6 (05) :337-343
[3]  
Amer Diabet Assoc, 2002, DIABETES CARE, V25, P213
[4]   Cardiovascular Disease and Risk Management [J].
不详 .
DIABETES CARE, 2015, 38 :S49-S57
[5]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[6]  
[Anonymous], NCHS DATA BRIEF
[7]  
[Anonymous], 1993, ARCH INTERN MED, V153, P154, DOI DOI 10.1001/ARCHINTE.1993.00410020010002
[8]  
[Anonymous], 2000, Lancet, V355, P253, DOI [10.1016/S0140-6736(99)12323-7, DOI 10.1016/S0140-6736(99)12323-7]
[9]   THE PROSPECTIVE CARDIOVASCULAR MUNSTER (PROCAM) STUDY - PREVALENCE OF HYPERLIPIDEMIA IN PERSONS WITH HYPERTENSION AND OR DIABETES-MELLITUS AND THE RELATIONSHIP TO CORONARY HEART-DISEASE [J].
ASSMANN, G ;
SCHULTE, H .
AMERICAN HEART JOURNAL, 1988, 116 (06) :1713-1724
[10]   Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
McGill, JB ;
Messerli, FH ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Oakes, R ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236